| Overview |
| bs-4974R-Cy5 |
| Glucose 6 Phosphate Dehydrogenase Antibody, Cy5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat, Cow, Sheep, Horse, Rabbit |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Glucose 6 Phosphate Dehydrogenase |
| 351-450/515 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm, Cell membrane |
| G6PD; G6PD_HUMAN; G6PD1; G6pdx; Glucose 6 phosphate 1 dehydrogenase; Glucose-6-phosphate 1-dehydrogenase; MET19; POS10; Zwf1p. |
| Defects in G6PD are the cause of chronic non-spherocytic hemolytic anemia (CNSHA) . Deficiency of G6PD is associated with hemolytic anemia in two different situations. First, in areas in which malaria has been endemic, G6PD-deficiency alleles have reached high frequencies (1% to 50%) and deficient individuals, though essentially asymptomatic in the steady state, have a high risk of acute hemolytic attacks. Secondly, sporadic cases of G6PD deficiency occur at a very low frequencies, and they usually present a more severe phenotype. Several types of CNSHA are recognized. Class-I variants are associated with severe NSHA; class-II have an activity <10% of normal; class-III have an activity of 10% to 60% of normal; class-IV have near normal activity. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz